期刊
CHILDREN-BASEL
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/children10020331
关键词
SARS-CoV-2; COVID-19; methotrexate; pediatric; renal failure; AKI
类别
This study investigated the occurrence of acute kidney injury in patients with concurrent SARS-CoV-2 infection during high-dose methotrexate (HDMTX) treatment. The results showed that all three patients who were infected with SARS-CoV-2 during HDMTX treatment developed acute kidney injury. Therefore, the researchers suggested that COVID-19 could be one of the causes of kidney failure in these patients.
Background. Methotrexate is renally excreted. HDMTX (high dose-methotrexate)-induced acute kidney injury (AKI) is a non-oliguric decrease in glomerular filtration rate (GFR) heralded by an acute rise in serum creatinine. Moreover, AKI is also a frequent complication of COVID-19. Among our patients treated with HDMTX, some of these developed AKI during SARS-CoV-2 infection. Therefore, we wondered whether our patients' kidney failure might have been triggered by their underlying SARS-CoV-2 positivity. Methods. Data were collected from the database at the Pediatric Oncology Unit of the Istituto Nazionale dei Tumori in Milan (Italy) regarding patients who matched the following selective criteria: (a) treatment with HDMTX during the pandemic period; (b) SARS-CoV-2 infection during the treatment; (c) development of AKI during HDMTX treatment and SARS-CoV-2 infection. Results. From March 2020 to March 2022, a total of 23 patients were treated with HDMTX; 3 patients were treated with HDMTX during SARS-CoV-2 infection and all 3 developed AKI. Conclusions. Clinical manifestations associated with this virus are many, so we are not yet able to lower our guard and rule out this infection as a cause of clinical manifestations with any certainty.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据